Table 4 Association between response designation and tumour intrinsic subtype for the correlative subset (n=46)a

From: A phase II study of sequential neoadjuvant gemcitabine plus doxorubicin followed by gemcitabine plus cisplatin in patients with operable breast cancer: prediction of response using molecular profiling

 

Pathologic Complete Response b

Clinical Response Designation b

Intrinsic subtype

Yes

No

CR

PR

SD

Luminal (A+B)

3

12

7

8

1

HER2+/ER−

3

4

1

6

1

Basal-like

7

7

7

7

3

  1. Correlative subset includes patients with pretreatment microarray data.
  2. b Clinical response was not determined for four patients who discontinued after one or two cycles. One patient with a CR was not included in the table because classification was normal breast-like.
Back to article page